Genesee Valley Trust Co. increased its position in Parexel International Corp. (NASDAQ:PRXL) by 10.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 9,656 shares of the company’s stock after buying an additional 877 shares during the period. Genesee Valley Trust Co.’s holdings in Parexel International Corp. were worth $607,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PRXL. LaSalle Street Capital Management LLC bought a new position in shares of Parexel International Corp. during the second quarter worth about $203,000. Magnetar Financial LLC bought a new position in shares of Parexel International Corp. during the first quarter worth about $215,000. LS Investment Advisors LLC boosted its position in shares of Parexel International Corp. by 64.0% in the second quarter. LS Investment Advisors LLC now owns 3,501 shares of the company’s stock worth $220,000 after buying an additional 1,366 shares during the last quarter. M&T Bank Corp bought a new position in shares of Parexel International Corp. during the first quarter worth about $276,000. Finally, Eqis Capital Management Inc. boosted its position in shares of Parexel International Corp. by 21.9% in the second quarter. Eqis Capital Management Inc. now owns 5,098 shares of the company’s stock worth $321,000 after buying an additional 916 shares during the last quarter. Institutional investors and hedge funds own 95.59% of the company’s stock.

Shares of Parexel International Corp. (NASDAQ:PRXL) traded up 1.11% on Wednesday, reaching $69.20. The company’s stock had a trading volume of 329,564 shares. The company has a market cap of $3.68 billion, a P/E ratio of 24.20 and a beta of 0.95. The company has a 50 day moving average price of $68.42 and a 200 day moving average price of $63.89. Parexel International Corp. has a 52-week low of $56.00 and a 52-week high of $71.13.

Parexel International Corp. (NASDAQ:PRXL) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.93 by $0.01. The company had revenue of $538.60 million for the quarter, compared to the consensus estimate of $532.41 million. Parexel International Corp. had a return on equity of 33.29% and a net margin of 6.44%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.79 EPS. On average, analysts anticipate that Parexel International Corp. will post $3.92 earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on the company. Robert W. Baird restated an “outperform” rating and issued a $73.00 target price on shares of Parexel International Corp. in a report on Monday, June 27th. Citigroup Inc. restated a “buy” rating and issued a $74.00 target price (up from $72.00) on shares of Parexel International Corp. in a report on Tuesday, July 5th. William Blair cut Parexel International Corp. from an “outperform” rating to a “market perform” rating in a report on Monday, July 18th. Jefferies Group restated a “hold” rating and issued a $70.00 target price on shares of Parexel International Corp. in a report on Thursday, June 9th. Finally, Zacks Investment Research cut Parexel International Corp. from a “hold” rating to a “sell” rating in a report on Thursday, June 30th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $71.75.

In related news, insider Gadi Saarony sold 2,500 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $70.05, for a total transaction of $175,125.00. Following the sale, the insider now owns 9,417 shares of the company’s stock, valued at approximately $659,660.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.70% of the company’s stock.

Parexel International Corp. Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Parexel International Corp. (NASDAQ:PRXL).

Receive News & Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.